A. de Kleyn

1.2k total citations · 1 hit paper
8 papers, 455 citations indexed

About

A. de Kleyn is a scholar working on Genetics, Molecular Biology and Surgery. According to data from OpenAlex, A. de Kleyn has authored 8 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 4 papers in Molecular Biology and 1 paper in Surgery. Recurrent topics in A. de Kleyn's work include Neurogenetic and Muscular Disorders Research (7 papers), RNA modifications and cancer (2 papers) and Pluripotent Stem Cells Research (2 papers). A. de Kleyn is often cited by papers focused on Neurogenetic and Muscular Disorders Research (7 papers), RNA modifications and cancer (2 papers) and Pluripotent Stem Cells Research (2 papers). A. de Kleyn collaborates with scholars based in United States, Italy and Switzerland. A. de Kleyn's co-authors include F Tukov, Sitra Tauscher‐Wisniewski, Deepa H. Chand, Jerry R. Mendell, Petra Kaufmann, Rui Sun, Hugh J. McMillan, F. Mohr, Gerd A. Kullak‐Ublick and Kyle H. Montgomery and has published in prestigious journals such as Neurology, Journal of Hepatology and JAMA Neurology.

In The Last Decade

A. de Kleyn

6 papers receiving 448 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy

2021 173 citations Jerry R. Mendell, Samiah Al-Zaidy et al. JAMA Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. de Kleyn United States	3	284	248	179	150	42	8	455
Kapil Arya United States	9	188 0.7×	170 0.7×	96 0.5×	102 0.7×	25 0.6×	23	372
Melissa Menier United States	5	207 0.7×	235 0.9×	90 0.5×	151 1.0×	27 0.6×	8	330
Markus McColly United States	5	269 0.9×	250 1.0×	87 0.5×	165 1.1×	15 0.4×	12	408
Natalie F. Reash United States	7	214 0.8×	153 0.6×	83 0.5×	97 0.6×	19 0.5×	20	314
Louise Deschênes Canada	5	298 1.0×	117 0.5×	40 0.2×	170 1.1×	30 0.7×	10	356
Tayaramma Thatava United States	13	392 1.4×	41 0.2×	146 0.8×	285 1.9×	18 0.4×	15	587
David Schorling Germany	10	325 1.1×	408 1.6×	76 0.4×	241 1.6×	5 0.1×	18	526
Nobuyuki Urasawa Japan	10	388 1.4×	57 0.2×	147 0.8×	113 0.8×	20 0.5×	15	583
Tushar Menon United States	7	407 1.4×	24 0.1×	106 0.6×	106 0.7×	47 1.1×	12	592
Chiara Palka Italy	10	255 0.9×	95 0.4×	210 1.2×	48 0.3×	4 0.1×	34	468

Countries citing papers authored by A. de Kleyn

Since Specialization

Citations

This map shows the geographic impact of A. de Kleyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. de Kleyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. de Kleyn more than expected).

Fields of papers citing papers by A. de Kleyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. de Kleyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. de Kleyn. The network helps show where A. de Kleyn may publish in the future.

Co-authorship network of co-authors of A. de Kleyn

This figure shows the co-authorship network connecting the top 25 collaborators of A. de Kleyn. A scholar is included among the top collaborators of A. de Kleyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. de Kleyn. A. de Kleyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Kleyn, A. de, et al.. (2026). Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database. Current Therapeutic Research. 104. 100826–100826.

2.

Mendell, Jerry R., Samiah Al-Zaidy, Kelly J. Lehman, et al.. (2021). Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurology. 78(7). 834–834. 173 indexed citations breakdown →

3.

Mendell, Jerry R., Richard S. Finkel, Eugenio Mercuri, et al.. (2021). Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA) (2301). Neurology. 96(15_supplement). 2 indexed citations

4.

Mendell, Jerry R., Richard S. Finkel, Eugenio Mercuri, et al.. (2021). SMA - TREATMENT. Neuromuscular Disorders. 31. S132–S133.

5.

Day, John, Jerry R. Mendell, Eugenio Mercuri, et al.. (2021). Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. Drug Safety. 44(10). 1109–1119. 81 indexed citations

6.

Shell, Richard, et al.. (2021). S11 Long-term follow-up of the phase 1 START trial of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1. A10.1–A10. 2 indexed citations

7.

Chand, Deepa H., F. Mohr, Hugh J. McMillan, et al.. (2020). Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. Journal of Hepatology. 74(3). 560–566. 196 indexed citations

8.

Chand, Deepa H., et al.. (2020). SMA – THERAPY. Neuromuscular Disorders. 30. S120–S121. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact